This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Chesney, J. et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2017.73.7379 (2017)
Rights and permissions
About this article
Cite this article
Romero, D. Gain beyond injection. Nat Rev Clin Oncol 14, 712–713 (2017). https://doi.org/10.1038/nrclinonc.2017.172
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.172